Feasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer


Objective: To evaluate the feasibility of S-1 and high-dose cisplatin short hydration regimens for outpatients with unresectable metastatic gastric cancer. Methods: Data for individual outpatients treated in our institution were retrospectively pooled to assess the feasibility of an S-1 and highdose cisplatin short hydration regimen (S-1: 80 to 120 mg on Days 1 to 21; cisplatin: 60 mg/m2 on Day 8, every 5 weeks), which included 2250 ml of intravenous fluids and 1000 ml oral hydration. Ten consecutive patients were treated with S-1 and high-dose cisplatin short hydration for unresectable metastatic gastric cancer from July 2011 to May 2012 and were included in the analysis. Results: With a median of 3.5 medication cycles, unscheduled admission occurred in two patients for 5 days each due to paralytic ileus and cerebral infarction. Four patients required dose reduction, in both S-1 and cisplatin in two patients, and in S-1 alone and cisplatin alone in one patient each. Renal function transiently declined after administration of cisplatin, but serum creatinine level and estimated glomerular filtration rate were both improved by the time of the next administration. Conclusion: This study suggests that an S-1 and high-dose cisplatin short hydration strategy for outpatients with unresectable metastatic gastric cancer might be feasible.

Share and Cite:

Satake, H. , Tsuji, A. , Kotake, T. and Fujita, M. (2014) Feasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer. Journal of Cancer Therapy, 5, 759-765. doi: 10.4236/jct.2014.58084.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Stewart, D.J., Dulberg, C.S., Mikhael, N.Z., Redmond, M.D., Montpetit, V.A. and Goel, R. (1997) Association of Cisplatin Nephrotoxicity with Patient Characteristics and Cisplatin Administration Methods. Cancer Chemotherapy and Pharmacology, 40, 293-308.
[2] Vogl, S.E., Zaravinos, T. and Kaplan, B.H. (1980) Toxicity of Cis-Diamminedichloroplatinum II Given in a Two-Hour Outpatient Regimen of Diuresis and Hydration. Cancer, 45, 11-15.
[3] Willox, J.C., McAllister, E.J., Sangster, G. and Kaye, S.B. (1986) Effects of Magnesium Supplementation in Testicular Cancer Patients Receiving Cis-Platin: A Randomised Trial. British Journal of Cancer, 54, 19-23. http://dx.doi.org/10.1038/bjc.1986.147
[4] Bodnar, L., Wcislo, G., Gasowska-Bodnar, A., Synowiec, A., Szarlej-Wcislo, K. and Szczylik, C. (2008) Renal Protection with Magnesium Subcarbonate and Magnesium Sulphate in Patients with Epithelial Ovarian Cancer after Cisplatin and Paclitaxel Chemotherapy: A Randomised Phase II Study. European Journal of Cancer, 44, 2608-2614. http://dx.doi.org/10.1016/j.ejca.2008.08.005
[5] Okazaki, S., Nakajima, T.E., Hashimoto, J., Yamamoto, S., Takahari, D., Kato, K., Hamaguchi, T., Yamada, Y., Shimada, Y. and Tamura, K. (2013) A Feasibility Study of Outpatient Chemotherapy with s-1 + Cisplatin in Patients with Advanced Gastric Cancer. Gastric Cancer, 16, 41-47.
[6] Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., Toh, Y., Nagaie, T., Takagi, S., Yamamura, Y., Yanaoka, K., Orita, H. and Takeuchi, M. (2008) S-1 plus Cisplatin versus s-1 Alone for First-Line Treatment of Advanced Gastric Cancer (Spirits Trial): A Phase III Trial. The Lancet Oncology, 9, 215-221.
[7] Tiseo, M., Martelli, O., Mancuso, A., Sormani, M.P., Bruzzi, P., Di Salvia, R., De Marinis, F. and Ardizzoni, A. (2007) Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma. Tumori, 93, 138-144.
[8] Sasaki, Y., Tamura, T., Eguchi, K., Shinkai, T., Fujiwara, Y., Fukuda, M., Ohe, Y., Bungo, M., Horichi, N., Niimi, S., Minato, K. and Nakagawa, K. (1989) Pharmacokinetics of (Glycolate-0,0’)-Diammine Platinum (II), a New Platinum Derivative, in Comparison with Cisplatin and Carboplatin. Cancer Chemotherapy and Pharmacology, 23, 243-246. http://dx.doi.org/10.1007/BF00451649
[9] Yamada, K., Yoshida, T., Zaizen, Y., Okayama, Y., Naito, Y., Yamashita, F., Takeoka, H., Mizoguchi, Y. and Azuma, K. (2011) Clinical Practice in Management of Hydration for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy in Japan: A Questionnaire Survey. Japanese Journal of Clinical Oncology, 41, 1308-1311. http://dx.doi.org/10.1093/jjco/hyr145
[10] Longo, F., Mansueto, G., Lapadula, V., Stumbo, L., Del Bene, G., Adua, D., De Filippis, L., Bonizzoni, E. and Quadrini, S. (2012) Combination of Aprepitant, Palonosetron and Dexamethasone as Antiemetic Prophylaxis in Lung Cancer Patients Receiving Multiple Cycles of Cisplatin-Based Chemotherapy. International Journal of Clinical Practice, 66, 753-757.
[11] Rapoport, B.L., Jordan, K., Boice, J.A., Taylor, A., Brown, C., Hardwick, J.S., Carides, A., Webb, T. and Schmoll, H.J. (2010) Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with a Broad Range of Moderately Emetogenic Chemotherapies and Tumor Types: A Randomized, Double-Blind Study. Support Care Cancer, 18, 423-431.
[12] Saito, M., Aogi, K., Sekine, I., Yoshizawa, H., Yanagita, Y., Sakai, H., Inoue, K., Kitagawa, C., Ogura, T. and Mitsuhashi, S. (2009) Palonosetron plus Dexamethasone versus Granisetron plus Dexamethasone for Prevention of Nausea and Vomiting during Chemotherapy: A Double-Blind, Double-Dummy, Randomised, Comparative Phase III Trial. The Lancet Oncology, 10, 115-124. http://dx.doi.org/10.1016/S1470-2045(08)70313-9

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.